1，2-二氨基-3-苯丙烷类氨肽酶N抑制剂的设计、合成及其活性研究
|
摘要
研究目的
氨肽酶N(Aminopeptidase N,APN),亦被称为CD13,是一类锌离子依赖性金属蛋白酶,广泛存在于小肠、肾及中枢神经系统的多种细胞表面。相比于正常细胞,该酶在肿瘤细胞表面高水平表达。研究证明氨肽酶N在肿瘤生长、侵袭和转移过程中发挥着重要作用:(1)降解细胞外基质,促进原发肿瘤的生长侵袭,有利于肿瘤的转移;(2)氨肽酶N是肿瘤新生血管的调节器,可以促进肿瘤新生血管的形成;(3)降解胸腺肽和白介素,降低机体免疫机能。世界卫生组织曾指出70%的晚期癌症患者出现明显的疼痛,癌症引起的疼痛亦是临床治疗癌症的一个难题,往往使用的是阿片类药物。研究报道生物体内具有阿片样物质,脑啡肽即是其中一个。但脑啡肽易被体内的氨肽酶N所降解,令其作为镇痛药具有局限性。
正因为氨肽酶N与肿瘤的密切关系,抗氨肽酶N药物的研究是抗肿瘤研究领域的一个热点。目前的研究主要包括氨肽酶N单抗,氨肽酶N配体药物和氨肽酶N抑制剂三方面。其中氨肽酶N单抗仅仅只是用于基础研究;氨肽酶N配体药物研究已有报道APN的特异性受体NGR(asparagine-glycine-arginine)与肿瘤药物偶联后取得令人满意的治疗效果。抗氨肽酶N药物研究较成熟的方面是氨肽酶N抑制剂的开发,Bestatin作为第一个上市的氨肽酶N抑制剂,临床上已经用于治疗急性成年人非淋巴性白血病。近年又发现许多氨肽酶N天然抑制剂,如Probestatin,Amastatin,Curcumin等;另外,人们还合成了许多小分子化合物氨肽酶N抑制剂,如α-氨基磷酸抑制剂,β-氨基硫醇类抑制剂等。本课题组以氨肽酶N为靶点,经十几年的研究亦报道了许多小分子类肽化合物。
本研究以氨肽酶N为靶点在充分调研文献的基础上,基于E.Coli氨肽酶N(eAPN)的三维晶体结构及bestatin与eAPN作用模式,通过计算机辅助合理药物设计,合成一系列小分子类肽化合物并对它们进行初步的活性筛选,以期找到具有良好的氨肽酶N抑制活性的先导化合物。
实验方法
目前为止人氨肽酶N的晶体结构尚未报道,2006年大肠杆菌氨肽酶N的晶体结构以及其与bestatin复合物的晶体结构陆续被报道。eAPN的晶体结构表明氨肽酶N活性区域至少包含有一个阴离子结合位点和三个疏水性口袋,即:位于锌离子左侧的S_1和右侧的S_1'和S_2'口袋。本研究以bestatin作为先导物,充分利用计算机辅助药物设计软件的优势,构建了一系列小分子化合物库,并对所建立的小分子化合物库进行虚拟筛选,寻找到与eAPN活性中心区域匹配良好的1,2-二氨基-3-苯丙烷骨架。利用计算机软件Sybyl将该骨架和bestatin的母核AHPA进行比对,发现二者与eAPN的活性中心作用模式相似,并且二者的溶剂可及化表面也极为相似。在构建的母核1,2-二氨基-3-苯丙烷结构基础上,然后将不同的结构片段与之拼接后再利用柔性对接模拟目标化合物与靶酶的作用模式,依此对1,2-二氨基-3-苯丙烷骨架的侧链进行结构修饰,合理设计目标化合物。
本研究以D-苯丙氨酸作为起始原料,经甲酯化、甲磺酰化、叠氮化及还原反应得到关键中间体(2R)-2-叔丁氧羰酰胺基-3-苯基-丙胺,再利用经典的二肽缩合反应,将不同的结构片段与之相拼接得到一系列二肽类化合物。第二系列类三肽化合物是在第一系列类二肽化合物基础上进行结构优化而来,将已制备的不同的二肽与(2R)-2-叔丁氧羰酰胺基-3-苯基-丙胺进行缩合反应,再将保护基团脱去得到一系列类三肽目标化合物。此外,本研究将目标化合物进行了体外抑酶实验、体外HL-60细胞生长测试实验,筛选有氨肽酶N抑制活性的化合物。
实验结果
本文共设计并合成了79个目标化合物,并对所有化合物通过红外光谱、核磁共振氢谱、电喷雾质谱等方法进行了结构确证。经查阅文献证实,所合成的目标化合物为新型化合物,未见文献报道。
本研究第一系列合成了38个以1,2-二氨基-3-苯丙烷为骨架结构的类二肽化合物,体外抑酶实验显示大部分化合物对氨肽酶N具有一定的抑制活性,化合物11j,11k,11p,21显示了良好的酶活性,但抑酶效果和对照物bestatin有一定的差距。分析化合物11j,11k,11p结构特征发现,化合物末端的极性基团(如羟基,巯基,氨基等)可以提高化合物的氨肽酶N抑制活性;另外,化合物21作为本系列中的一个类三肽化合物,显示了不错的抑制活性,推测与其结构有关。在第一系列化合物活性结果基础上,我们以第一系列中11p和21作为先导物,对其进行结构修饰和优化,设计并合成了41个类三肽化合物,体外抑酶实验显示本系列相比于第一系列化合物,活性有明显提高。从结构上来讲,第二系列类三肽化合物与氨肽酶N的活性中心的作用优于类二肽化合物,骨架的苯环可以伸入活性中心的S_1疏水性口袋,而两个侧链R和R_1分别伸向S_1'和S_2'口袋。其中化合物32d,44a,44d,44h的IC_(50)在10μM以下,接近于对照物Bestatin(IC_(50):3.1±0.6μM)的氨肽酶N抑制活性。
体外细胞实验通过MTT法测定了目标化合物对白血病细胞HL-60的生长抑制作用,结果显示对APN酶抑制作用强的化合物11p,21,32d,44a,44d和44h同样有很强的HL-60细胞抑制活性,化合物32d和44h的IC_(50)分别为0.29±0.06mM和0.27±0.08mM,超过了bestatin。此外,基于氨肽酶N在脑啡肽降解过程中发挥着关键作用,本文建立了两套氨肽酶N抑制剂筛选体系用来更好的考察新型氨肽酶N抑制剂的活性。无论是豚鼠回肠平滑肌电针刺激实验体系,还是HPLC检测二肽Tyr-Gly在豚鼠脑蛋白中降解的实验体系,都可以很好地用于评价氨肽酶N新型抑制剂的活性。
最后,本文在1,2-二氨基-3-苯丙烷类氨肽酶N抑制剂活性结果基础上,以所合成的化合物为对象,利用计算机软件进行了初步的定量构效关系研究。分子对接研究通过化合物44h的分子对接模式图解析了本课题中氨肽酶N抑制剂与氨肽酶N活性中心的作用位点及作用模式。化合物44h的苯环,赖氨酸侧链及巯基侧链分别占据氨肽酶N活性区域的三个疏水性口袋S_1,S_1'和S_2',抑制剂与氨肽酶N活性中心区域匹配良好。采用比较分子场分析方法(CoMFA)建立了1,2-二氨基-3-苯丙烷类氨肽酶N抑制剂的定量构效关系(QSAR)模型。通过对CoMFA模型立体场等势线图和静电场等势线图的分析,建立的CoMFA模型具有较高的交叉验证系数q~2和一定的预测能力。
研究结论
本研究基于氨肽酶N的晶体结构及抑制剂与酶的作用模式,利用计算机软件进行设计并合成的1,2-二氨基-3-苯丙烷类化合物具有很好的氨肽酶N抑制活性。所设计的合成路线科学合理,原料经济易得。通过初步的活性测试发现了具有进一步研究价值的化合物。基于化合物结构和活性数据建立了有一定预测能力的定量构效关系模型,为今后新型氨肽酶抑制剂的研究提供了帮助。
Objective
Aminopeptidase N(APN),as known as CD13,is a member of zinc dependent metalloproteinase.It is widely expressed on the surface of renal and intestinal brush border cells,synaptic membranes in central systems and APN is over-expressed on the surface of tumor cells.APN is demonstrated to play a key role in the process of tumor growth,invasion and metastasis.The functional aspects are briefly summarized:(1). Degrading extracellular matrix,promoting the growth and invasion of tumor cells;(2). As a regulator of novel vessels,promoting the angiogenesis of tumor tissues;(3). Degrading immunoactive substance and bioactive peptides,such as interleukin, thymopentin,enkephalin and so on.Additionally,World Health Organization(WHO) had reported that 70%terminal cancer patients usually suffer the pain.Synthetic analogues of morphine are applied as analgesics but they have undesirable side effects (e.g.addiction).Numerous researches have shown that one of the most promising approaches appears to potentiate the antinociceptive effected induced by the endogenous opioid substance enkephalin.However,enkephalin is limited in the clinical therapy for easily degradation by aminopeptidase N.
More and more researches focus on the field of anti-aminopeptidase N drug as that enzyme has the close relationship with the cancer.The research mainly contained APN mono-antibody,APN ligand binding drug and aminopeptidase N inhibitor.APN mono-antibody is only for research at this time and some reports have showed that APN ligand NGR(asparagine-glycine-arginine) as the receptor of APN linked with anticancer drug can get well therapeutic effect.Most of the research on the anti-aminopeptidase N drug is to find aminopeptidase N inhibitor possessed inhibitory activity.Bestatin,the marketed drug as aminopeptidase N inhibitor,now is clinically used to prolong the survival of patients with acute adult nonlymphcytic leukemia.In recent years,many natural aminopeptidase N inhibitors have been reported,such as Probestatin,Amastatin and Curcumin.Moreover,numerous synthetic APN inhibitors have also been reported,such asα-aminophosphonates APN inhibitors,β-amino-thiols APN inhibitors.In our group,we also had reported numerous synthetic small molecular compounds targeted with aminopeptidase N in the past ten years.
Based on the three dimensional crystal structure of E.Coli APN and enzyme-bestatin complex,this study used computer-aided drug design software to design and synthesize a series of compounds.Then we hope to find lead compounds which possess potential aminopeptidase N inhibitory activity.
Methods
So far the three dimensional structure of human APN has not been found and the crystal structure of E.Coli aminopeptidase N was reported in 2006.As the structure of lead compound bestatin,we build a virtual molecule library with the advantages of computer-aided drug design software.The following design strategy is screening the virtual molecule library to obtain the pharmacophore 3-phenylpropane-1,2-diamine, which could satisfy the requirement of the active site of E.Coli APN.We compared the mode of the pharmacophore and AHPA with the active site of APN by the Sybyl 7.0.The result showed that the electrostatic potential surface of 3-phenylpropane-1, 2-diamine and AHPA is very similar.Based on the pharmacophore 3-phenylpropane-1, 2-diamine,various fragments are introduced with the pharmacophore by the FlexX docking aided and virtual screened.As a result,the target compounds are design rationally and synthesized easily.
In this research,the D-phenylalanine was used as the starting material.The phenylalanine was suffered esterification,sulfonylation,nitridation and reduction to get the key intermediate(2R)-2-[(tert-butoxycarbonyl)amino]-3-phenyl-propylamine. Then various fragments were coupled with the intermediate to generate a series of dipeptidemimatics.The compounds of seriesⅡare designed based on the optimization of the seriesⅠ.The intermediate was coupled with different prepared dipeptide to generate various analogues of tripeptide.In addition,enzyme assay and HL-60 cell proliferation assay were processed in this research.
Results
In this research,we obtained 79 target compounds and all of them are novel without any report by now with the structures identified by IR,~1H-NMR and ESI-MS.
In series I,we designed and synthesized 38 analogous of dipeptide with the scaffold 3-phenylpropane-1,2-diamine.The enzyme assay showed that most compounds exhibited APN inhibitory activities and the most potential compounds are compound 11p and 21 and compound 11j,11k also exhibited well activity against APN.From the structure of compound 11j,11k and 11p,we know the polar group(e.g.-OH,-SH, -NH_2) of the compound can increase the activity of the compound.In addition, compound 21 is an analogue of tripeptide and shows the best APN inhibitory activity, maybe owing to the structure difference of the compound 21.Base on the results of the seriesⅠ,we optimized the structure of compounds with the compound 11p and 21 as lead compound.In this series,we obtained 41 target compounds and preliminary result showed that most of target compounds displayed better APN inhibitory activities than the seriesⅠ.The compounds in seriesⅡstructurally matched the active of the enzyme are better than these of compound in seriesⅠ.When the compounds in seriesⅡwere matched with the enzyme,the phenyl group of the pharmacophore could inserted to the S_1 pocket,and two side chains R,R_1 inserted to the S_1' and S_2', respectively.The IC_(50) of compound 32d,44a,44d,44h are less than 10μM,which are similar to that of bestatin.
The results of in vitro growth inhibition against HL-60 cells indicated that most potent APN inhibitor displayed good inhibitory effect against the growth of HL-60 cells.Compound 11p,21,32d,44a,44d and 44h,which showed well enzyme inhibitory activities against APN,also exhibited good potency against the proliferation of HL-60 cell.Moreover,compound 32d,44h exhibited the inhibitory effect of cell proliferation with IC_(50) values of 0.29±0.06 mM and 0.27±0.08 mM,respectively, which showed better potency than that of bestatin.
Additionally,based on the key role of APN in the process of degradation of enkephalin,we established two useful systems for the in vitro evaluation of the novel APN inhibitor.Potentiating effect of APN inhibitors on the twitch inhibition of enkephalin in guinea pig ileum experiment and effects of APN inhibitors on the hydrolysis of Tyr-Gly during the incubation with the striatal membrane of guinea pig experiment,both of them could be used to evaluate the activity of novel APN inhibitor.
Finally,the structure activity relationship(SAR) was showed based on the structure and the activity data of the target compounds with the scaffold 3-phenylpropane-1,2-diamine.In order to investigate the interaction of our target compounds with APN, flexible docking of the compound 44h was built and docked into the active site of APN(PDB code:2DQM) using Sybyl7.0.The binding studies showed the phenyl group inserted to S_1 pocket,the thiol group orientated to S_1' pocket and the lysine side chain plunged into pocket S_2' Comparative Molecular Field Analysis(CoFAR) was utilized to establish the quantitative structure activity relationship(QSAR) of the target compounds.The steric contour map and the electrostatic contour map of the CoMFA model showed the model had good cross-validated coefficient q~2 and predictive potency.
Conclusions
In conclusion,based on the crystal structure of eAPN and the mode of bestatin with the enzyme,we utilize the computer-aided drug design software to design and synthesize the target compounds with the scaffold 3-phenylpropane-1,2-diamine.We reported a convenient and economical method of the synthesis of APN inhibitors. Preliminary activity assays showed most compounds possess APN inhibitory activity and the IC_(50) of compound 32d,44a,44d,44h is less than 10μM which can be used in the further research.We also established a QASR model of target compounds which is beneficial for the design APN inhibitor in the future.
氨肽酶N(Aminopeptidase N,APN),亦被称为CD13,是一类锌离子依赖性金属蛋白酶,广泛存在于小肠、肾及中枢神经系统的多种细胞表面。相比于正常细胞,该酶在肿瘤细胞表面高水平表达。研究证明氨肽酶N在肿瘤生长、侵袭和转移过程中发挥着重要作用:(1)降解细胞外基质,促进原发肿瘤的生长侵袭,有利于肿瘤的转移;(2)氨肽酶N是肿瘤新生血管的调节器,可以促进肿瘤新生血管的形成;(3)降解胸腺肽和白介素,降低机体免疫机能。世界卫生组织曾指出70%的晚期癌症患者出现明显的疼痛,癌症引起的疼痛亦是临床治疗癌症的一个难题,往往使用的是阿片类药物。研究报道生物体内具有阿片样物质,脑啡肽即是其中一个。但脑啡肽易被体内的氨肽酶N所降解,令其作为镇痛药具有局限性。
正因为氨肽酶N与肿瘤的密切关系,抗氨肽酶N药物的研究是抗肿瘤研究领域的一个热点。目前的研究主要包括氨肽酶N单抗,氨肽酶N配体药物和氨肽酶N抑制剂三方面。其中氨肽酶N单抗仅仅只是用于基础研究;氨肽酶N配体药物研究已有报道APN的特异性受体NGR(asparagine-glycine-arginine)与肿瘤药物偶联后取得令人满意的治疗效果。抗氨肽酶N药物研究较成熟的方面是氨肽酶N抑制剂的开发,Bestatin作为第一个上市的氨肽酶N抑制剂,临床上已经用于治疗急性成年人非淋巴性白血病。近年又发现许多氨肽酶N天然抑制剂,如Probestatin,Amastatin,Curcumin等;另外,人们还合成了许多小分子化合物氨肽酶N抑制剂,如α-氨基磷酸抑制剂,β-氨基硫醇类抑制剂等。本课题组以氨肽酶N为靶点,经十几年的研究亦报道了许多小分子类肽化合物。
本研究以氨肽酶N为靶点在充分调研文献的基础上,基于E.Coli氨肽酶N(eAPN)的三维晶体结构及bestatin与eAPN作用模式,通过计算机辅助合理药物设计,合成一系列小分子类肽化合物并对它们进行初步的活性筛选,以期找到具有良好的氨肽酶N抑制活性的先导化合物。
实验方法
目前为止人氨肽酶N的晶体结构尚未报道,2006年大肠杆菌氨肽酶N的晶体结构以及其与bestatin复合物的晶体结构陆续被报道。eAPN的晶体结构表明氨肽酶N活性区域至少包含有一个阴离子结合位点和三个疏水性口袋,即:位于锌离子左侧的S_1和右侧的S_1'和S_2'口袋。本研究以bestatin作为先导物,充分利用计算机辅助药物设计软件的优势,构建了一系列小分子化合物库,并对所建立的小分子化合物库进行虚拟筛选,寻找到与eAPN活性中心区域匹配良好的1,2-二氨基-3-苯丙烷骨架。利用计算机软件Sybyl将该骨架和bestatin的母核AHPA进行比对,发现二者与eAPN的活性中心作用模式相似,并且二者的溶剂可及化表面也极为相似。在构建的母核1,2-二氨基-3-苯丙烷结构基础上,然后将不同的结构片段与之拼接后再利用柔性对接模拟目标化合物与靶酶的作用模式,依此对1,2-二氨基-3-苯丙烷骨架的侧链进行结构修饰,合理设计目标化合物。
本研究以D-苯丙氨酸作为起始原料,经甲酯化、甲磺酰化、叠氮化及还原反应得到关键中间体(2R)-2-叔丁氧羰酰胺基-3-苯基-丙胺,再利用经典的二肽缩合反应,将不同的结构片段与之相拼接得到一系列二肽类化合物。第二系列类三肽化合物是在第一系列类二肽化合物基础上进行结构优化而来,将已制备的不同的二肽与(2R)-2-叔丁氧羰酰胺基-3-苯基-丙胺进行缩合反应,再将保护基团脱去得到一系列类三肽目标化合物。此外,本研究将目标化合物进行了体外抑酶实验、体外HL-60细胞生长测试实验,筛选有氨肽酶N抑制活性的化合物。
实验结果
本文共设计并合成了79个目标化合物,并对所有化合物通过红外光谱、核磁共振氢谱、电喷雾质谱等方法进行了结构确证。经查阅文献证实,所合成的目标化合物为新型化合物,未见文献报道。
本研究第一系列合成了38个以1,2-二氨基-3-苯丙烷为骨架结构的类二肽化合物,体外抑酶实验显示大部分化合物对氨肽酶N具有一定的抑制活性,化合物11j,11k,11p,21显示了良好的酶活性,但抑酶效果和对照物bestatin有一定的差距。分析化合物11j,11k,11p结构特征发现,化合物末端的极性基团(如羟基,巯基,氨基等)可以提高化合物的氨肽酶N抑制活性;另外,化合物21作为本系列中的一个类三肽化合物,显示了不错的抑制活性,推测与其结构有关。在第一系列化合物活性结果基础上,我们以第一系列中11p和21作为先导物,对其进行结构修饰和优化,设计并合成了41个类三肽化合物,体外抑酶实验显示本系列相比于第一系列化合物,活性有明显提高。从结构上来讲,第二系列类三肽化合物与氨肽酶N的活性中心的作用优于类二肽化合物,骨架的苯环可以伸入活性中心的S_1疏水性口袋,而两个侧链R和R_1分别伸向S_1'和S_2'口袋。其中化合物32d,44a,44d,44h的IC_(50)在10μM以下,接近于对照物Bestatin(IC_(50):3.1±0.6μM)的氨肽酶N抑制活性。
体外细胞实验通过MTT法测定了目标化合物对白血病细胞HL-60的生长抑制作用,结果显示对APN酶抑制作用强的化合物11p,21,32d,44a,44d和44h同样有很强的HL-60细胞抑制活性,化合物32d和44h的IC_(50)分别为0.29±0.06mM和0.27±0.08mM,超过了bestatin。此外,基于氨肽酶N在脑啡肽降解过程中发挥着关键作用,本文建立了两套氨肽酶N抑制剂筛选体系用来更好的考察新型氨肽酶N抑制剂的活性。无论是豚鼠回肠平滑肌电针刺激实验体系,还是HPLC检测二肽Tyr-Gly在豚鼠脑蛋白中降解的实验体系,都可以很好地用于评价氨肽酶N新型抑制剂的活性。
最后,本文在1,2-二氨基-3-苯丙烷类氨肽酶N抑制剂活性结果基础上,以所合成的化合物为对象,利用计算机软件进行了初步的定量构效关系研究。分子对接研究通过化合物44h的分子对接模式图解析了本课题中氨肽酶N抑制剂与氨肽酶N活性中心的作用位点及作用模式。化合物44h的苯环,赖氨酸侧链及巯基侧链分别占据氨肽酶N活性区域的三个疏水性口袋S_1,S_1'和S_2',抑制剂与氨肽酶N活性中心区域匹配良好。采用比较分子场分析方法(CoMFA)建立了1,2-二氨基-3-苯丙烷类氨肽酶N抑制剂的定量构效关系(QSAR)模型。通过对CoMFA模型立体场等势线图和静电场等势线图的分析,建立的CoMFA模型具有较高的交叉验证系数q~2和一定的预测能力。
研究结论
本研究基于氨肽酶N的晶体结构及抑制剂与酶的作用模式,利用计算机软件进行设计并合成的1,2-二氨基-3-苯丙烷类化合物具有很好的氨肽酶N抑制活性。所设计的合成路线科学合理,原料经济易得。通过初步的活性测试发现了具有进一步研究价值的化合物。基于化合物结构和活性数据建立了有一定预测能力的定量构效关系模型,为今后新型氨肽酶抑制剂的研究提供了帮助。
Objective
Aminopeptidase N(APN),as known as CD13,is a member of zinc dependent metalloproteinase.It is widely expressed on the surface of renal and intestinal brush border cells,synaptic membranes in central systems and APN is over-expressed on the surface of tumor cells.APN is demonstrated to play a key role in the process of tumor growth,invasion and metastasis.The functional aspects are briefly summarized:(1). Degrading extracellular matrix,promoting the growth and invasion of tumor cells;(2). As a regulator of novel vessels,promoting the angiogenesis of tumor tissues;(3). Degrading immunoactive substance and bioactive peptides,such as interleukin, thymopentin,enkephalin and so on.Additionally,World Health Organization(WHO) had reported that 70%terminal cancer patients usually suffer the pain.Synthetic analogues of morphine are applied as analgesics but they have undesirable side effects (e.g.addiction).Numerous researches have shown that one of the most promising approaches appears to potentiate the antinociceptive effected induced by the endogenous opioid substance enkephalin.However,enkephalin is limited in the clinical therapy for easily degradation by aminopeptidase N.
More and more researches focus on the field of anti-aminopeptidase N drug as that enzyme has the close relationship with the cancer.The research mainly contained APN mono-antibody,APN ligand binding drug and aminopeptidase N inhibitor.APN mono-antibody is only for research at this time and some reports have showed that APN ligand NGR(asparagine-glycine-arginine) as the receptor of APN linked with anticancer drug can get well therapeutic effect.Most of the research on the anti-aminopeptidase N drug is to find aminopeptidase N inhibitor possessed inhibitory activity.Bestatin,the marketed drug as aminopeptidase N inhibitor,now is clinically used to prolong the survival of patients with acute adult nonlymphcytic leukemia.In recent years,many natural aminopeptidase N inhibitors have been reported,such as Probestatin,Amastatin and Curcumin.Moreover,numerous synthetic APN inhibitors have also been reported,such asα-aminophosphonates APN inhibitors,β-amino-thiols APN inhibitors.In our group,we also had reported numerous synthetic small molecular compounds targeted with aminopeptidase N in the past ten years.
Based on the three dimensional crystal structure of E.Coli APN and enzyme-bestatin complex,this study used computer-aided drug design software to design and synthesize a series of compounds.Then we hope to find lead compounds which possess potential aminopeptidase N inhibitory activity.
Methods
So far the three dimensional structure of human APN has not been found and the crystal structure of E.Coli aminopeptidase N was reported in 2006.As the structure of lead compound bestatin,we build a virtual molecule library with the advantages of computer-aided drug design software.The following design strategy is screening the virtual molecule library to obtain the pharmacophore 3-phenylpropane-1,2-diamine, which could satisfy the requirement of the active site of E.Coli APN.We compared the mode of the pharmacophore and AHPA with the active site of APN by the Sybyl 7.0.The result showed that the electrostatic potential surface of 3-phenylpropane-1, 2-diamine and AHPA is very similar.Based on the pharmacophore 3-phenylpropane-1, 2-diamine,various fragments are introduced with the pharmacophore by the FlexX docking aided and virtual screened.As a result,the target compounds are design rationally and synthesized easily.
In this research,the D-phenylalanine was used as the starting material.The phenylalanine was suffered esterification,sulfonylation,nitridation and reduction to get the key intermediate(2R)-2-[(tert-butoxycarbonyl)amino]-3-phenyl-propylamine. Then various fragments were coupled with the intermediate to generate a series of dipeptidemimatics.The compounds of seriesⅡare designed based on the optimization of the seriesⅠ.The intermediate was coupled with different prepared dipeptide to generate various analogues of tripeptide.In addition,enzyme assay and HL-60 cell proliferation assay were processed in this research.
Results
In this research,we obtained 79 target compounds and all of them are novel without any report by now with the structures identified by IR,~1H-NMR and ESI-MS.
In series I,we designed and synthesized 38 analogous of dipeptide with the scaffold 3-phenylpropane-1,2-diamine.The enzyme assay showed that most compounds exhibited APN inhibitory activities and the most potential compounds are compound 11p and 21 and compound 11j,11k also exhibited well activity against APN.From the structure of compound 11j,11k and 11p,we know the polar group(e.g.-OH,-SH, -NH_2) of the compound can increase the activity of the compound.In addition, compound 21 is an analogue of tripeptide and shows the best APN inhibitory activity, maybe owing to the structure difference of the compound 21.Base on the results of the seriesⅠ,we optimized the structure of compounds with the compound 11p and 21 as lead compound.In this series,we obtained 41 target compounds and preliminary result showed that most of target compounds displayed better APN inhibitory activities than the seriesⅠ.The compounds in seriesⅡstructurally matched the active of the enzyme are better than these of compound in seriesⅠ.When the compounds in seriesⅡwere matched with the enzyme,the phenyl group of the pharmacophore could inserted to the S_1 pocket,and two side chains R,R_1 inserted to the S_1' and S_2', respectively.The IC_(50) of compound 32d,44a,44d,44h are less than 10μM,which are similar to that of bestatin.
The results of in vitro growth inhibition against HL-60 cells indicated that most potent APN inhibitor displayed good inhibitory effect against the growth of HL-60 cells.Compound 11p,21,32d,44a,44d and 44h,which showed well enzyme inhibitory activities against APN,also exhibited good potency against the proliferation of HL-60 cell.Moreover,compound 32d,44h exhibited the inhibitory effect of cell proliferation with IC_(50) values of 0.29±0.06 mM and 0.27±0.08 mM,respectively, which showed better potency than that of bestatin.
Additionally,based on the key role of APN in the process of degradation of enkephalin,we established two useful systems for the in vitro evaluation of the novel APN inhibitor.Potentiating effect of APN inhibitors on the twitch inhibition of enkephalin in guinea pig ileum experiment and effects of APN inhibitors on the hydrolysis of Tyr-Gly during the incubation with the striatal membrane of guinea pig experiment,both of them could be used to evaluate the activity of novel APN inhibitor.
Finally,the structure activity relationship(SAR) was showed based on the structure and the activity data of the target compounds with the scaffold 3-phenylpropane-1,2-diamine.In order to investigate the interaction of our target compounds with APN, flexible docking of the compound 44h was built and docked into the active site of APN(PDB code:2DQM) using Sybyl7.0.The binding studies showed the phenyl group inserted to S_1 pocket,the thiol group orientated to S_1' pocket and the lysine side chain plunged into pocket S_2' Comparative Molecular Field Analysis(CoFAR) was utilized to establish the quantitative structure activity relationship(QSAR) of the target compounds.The steric contour map and the electrostatic contour map of the CoMFA model showed the model had good cross-validated coefficient q~2 and predictive potency.
Conclusions
In conclusion,based on the crystal structure of eAPN and the mode of bestatin with the enzyme,we utilize the computer-aided drug design software to design and synthesize the target compounds with the scaffold 3-phenylpropane-1,2-diamine.We reported a convenient and economical method of the synthesis of APN inhibitors. Preliminary activity assays showed most compounds possess APN inhibitory activity and the IC_(50) of compound 32d,44a,44d,44h is less than 10μM which can be used in the further research.We also established a QASR model of target compounds which is beneficial for the design APN inhibitor in the future.
引文
[1].Jeffery,C.J.Moonlighting proteins:old proteins learning new tricks[J].Trends Genet.2003,19,415-417.
[2].Hooper N.M.Families of zinc metalloproteases[J].FEBS Lett.,1994,354(1):1-6.
[3].Antczak C.,De Meester I.,Bauvois B.Ectopeptidases in pathophysiology[J].Bioessays.2001,23(3):251-260.
[4].Flavio C.,Angelo,C.Differentiation binding of drugs containing the NGR motif to CDI3isoforms in tumor vessels,epithelia,and myeloid cells[J].Cancer Research.2002,62,867-874.
[5].Bauvois B.,Dauzonne D.Aminopeptidase-N/CD13(EC 3.4.11.2) inhibitors:chemistry,biological evaluations,and therapeutic prospects[J].Med.Res.Rev.,2006,26(1):88-130.
[6].Firla B.,Arndt M.,Frank K.,et al.Extracellular cysteines define ectopeptidase(APN,CD13)expression and function[J].Free Radical Biology Medicine,2002,32(7):584-595.
[7].Vlahovic P.,Stefanovic V.Kidney ectopeptidases.Structure,functions and clinical significance[J].Pathol Biol(Paris),1998,46(10):779-786.
[8].Noble F.,Banisadr G.,Jardinaud F.,et al.First discrete autoradiographic distribution of aminopeptidase N in various structure of rat brain and spinal cord using the selective iodinated inhibitor[125I]RB 129[J].Neuroscience,2001,105(2):479-488.
[9].Waksman G.,Bouboutou R.,Devin J.,et al.In vitro and in vivo effects of kelatorphan on enkephalin metabolism in rodent brain[J].Eur.J..Pharmacol.1985,117(2):233-243.
[10].Montiel J.L.,Cornille F.,Roques B.P.,et al.Nocieeptin/orphanin FQ metabolism:role of aminopeptidase and endopeptidase 24.15[J].J..Neurochem.1997,68(1 ):354-361.
[11].Sato Y.Role of aminopeptidase in angiogenesis[J].Biol.Pharm.Bull.,2004,27(6):772-776.
[12].Saiki I.,Fujii H.,Yoneda J.,et al.Role of aminopeptidase N(CD13) in tumor-cell invasion and extracellular matrix degradation[J].Int.J.Cancer,1993,54(1),137-143.
[13].Menrad A.,Speieher D.,Wacker J.,et al.Biochemical and functional characterization of aminopeptidase N expressed by human melanoma cells[j].Cancer Res.,1993,53(6):1450-1455.
[14].Gros C.,Giros B.,Schwartz J.C.Identification of aminopeptidase M as an enkephalin-inactivating enzyme in rat cerebral membranes[J].Biochemistry,1985,24(9):2179-2185.
[15].BalogT.,Marotti T.,SverkoV.,et al.Enkephalin degradating enzymes,in pheochromocytoma patients[J].Oncol.Rep.,2003,10(1):253-258.
[16].Mitsui T.,Nomura S.,Itakura A.,et al.Role of aminopeptidases in the blood pressure regulation[J].Biol.Pharm.Bull.,2004,27(6):768-771.
[17].Hattori A.,Tsujimoto M.Processing of antigenic peptides by aminopeptidases[J].Biol.Pharm.Bull.,2004,27(6):777-780.
[18]Bedir A.,Ozener I.C.,Emerk K.Urinary leucine aminopeptidase is a more sensitive indicator of early renal damage in non-insulin-dependent diabetics than microalbuminuria[J].Nephron,1996,74(1):110-113.
[19].ShimizuT.,Tani K.,HaseK.,et al.CD13/aminopeptidase N-induced lymphocyte involvement in inflamed joints of patients with rheumatoid arthritis[J].Arthritis.Rheum.,2002,46(9),2330-2338.
[20].Sloane P.D.,Zimmerman S.,Suchindran C.,et al.The public health impact of Alzheimer's disease,2000-2050:potential implication of treatment advances[J].Annu.Rev.Public Health,2002,23:213-231.
[21].Bauvois B.,Dauzonne D.Aminopeptidase-N/CD13(EC 3.4.11.2) inhibitors:chemistry,biological evaluations,and therapeutic prospects[J].Med.Res.Rev.,2006,26(1):88-130.
[22].Look A.T.,Ashmun R.A.,Shapiro L.H.,et al.Human myeloid plasma membrane glyeoprotein CDl3(gp150) is identical to aminopeotidase N[J].J.Clin.Invest.,1989,83(4):1299-1307.
[23].Soderberg C.,Giugni T.D.,Zaia J.A.,et al.CD13(human aminopeptidase N) mediates human eytomegalovirus infection[J].J.Virol.1993,67(11):6576-6585.
[24].Paola Mina-Osorio.The moonlighting enzyme CD13:old and new functions to target.Trends Mol Med.2008,14(8):361-71.
[25]Mitsui T.,Nomura S.,Itakura A.,et al.Role of aminopeptidases in the blood pressure regulation[J].Biol.Pharm.Bull.,2004,27(6):765-771.
[26].Salki I.,Fujii H.,Yoneda J.,et al.Role of aminopeptidase N(CD13) in tumor-cell invasion and extracellular matrix degradation[J].Int.J.Cancer,1993,54(1),137-143.
[27]Fujii H.,Nakajima M.,Saiki I.,et al.Human melanoma invasion and metastasis enhancement by high expression of aminopeptidase N/CD13[J].Clin.Exp.Metastasis,1995,13(5):337-344.
[28].Dixon J.,Kaklamanis L.,Turley H.,et al.Expression of aminopeptidase-n(CD 13) in normal tissues and malignant neoplasms of epithelial and lymphoid origin[J].J.Clin.Pathol.,1994,47(1):43-47.
[29].Sato Y.Role of aminopeptidase in angiogenesis[J].Biol.Pharm.Bull.,2004,27(6):772-776.
[30].Ishii K.,Usui S.,Sugimura Y.,et al.Aminopeptidase N regulated by zinc in human prostate participates in tumor cell invasion[J].Int.J.Cancer,2001,92(1):49-54.
[31].Kido A.,Krueger S.,Haeekel C.,et al.Inhibitory effect of antisense aminopeptidase N (APN/CD13) cDNA transfection on the invasive potential of osteosarcoma cells[J].Clin.Exp.Metastasis,2003,20(7):585-592.
[32].Hanahan D.,Folkman J.Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis[J].Cell,1996,86(3):353-364.
[33]Bhagwat S.V.,Petrovie N.,Okamoto Y.,et al.The angiogenie regulator CD13/APN is a transcriptional target of Ras signaling pathways in endothelial morphogenesis[J].Blood,2003,101(5):1818-1826.
[34].Ikeda N.,Nakajima Y.,Tokuhara T.et al.Clinical Significance of Aminopeptidase N/CD13Expression in Human Pancreatic Carcinoma[J].Clin.Cancer Res,,2003,9(4):1503-1508.
[35].Aozuka Y.,Koizumi K.,Saitoh Y.,et al:Anti-tumor angiogenesis effect of aminopeptidase inhibitor bestatin against B 16-BL6 melanoma cells orthotopically implanted into syngeneie mice[J].Cancer Lett.,2004,216(1):35-42.
[36].Bauvois B.Transmembrane proteases in cell growth and invasion:new contributors to angiogenesis[J].Oncogene,2004,23(2):317-329.
[37].Zetter B.R.Angiogenesis and tumor metastasis[J].Annu.Rev.Med,1995,49:407-424.
[38].Bussolino F.,Mantovani A.,Persico G.Molecular mechanisms of blood vessel formation[J].Trends Biochem.Sci.,1997,22(7):251-256.
[39].Scornik O.A.,Botbol V..Bestatin as experimental tool in mammals[J].Curr.Drug Metab., 2001,2(1):67-85.
[40].Alexander N.S.,Juergen Langner,Manfred Hem,ann,et al.Aminopeptadase N/CD13 is directly linked to signal transduction pathways in monocytes[J].Cell.Immunol.,2000,201(1):22-32
[41].Tani K.,Ogushi E,Huang L.,et al.CD13/aminopeptidase N,a Novel Chemoattractant for T Lymphocytes in Pulmonary Sarcoidosis[J].Am.J.Respir Crit.Care Med.,2000,161(5):1636-1642.
[42].Lohn M.,Mueller C.,Langner J.Cell cycle retardation in monocytoid cells induced by aminopeptidase N(CD13)[J].Leuk.Lymphoma.,2002,43(2):407-413.
[43].Cohen M.L.,Geary L.E.,Wiley K.S.Enkephalin degradation in the guinea-pig ileum:effect of aminopeptidase inhibitors,puromycin,and bestatin[J].J.Pharmacol.Exp.Ther.1983,224(2):379-385.
[44].Abroad S.,Wang L.,Ward P.E.Dipeptidyl(amino) peptidase Ⅳ and aminopeptidase M metabolize circulating substance P in vivo[J].J.Pharmacol.Exp.Ther,1992,260(3):1257-1261.
[45].Furuhashi M.,Mizutani S.,Kurauchi,O.,et al.In vitro degradation of opioid peptides by human placental aminopeptidase M[J].Exp.Clin.Endocrinol.,1988,92(2):235-237.
[46]Mansour A,Khachaturian H,Lewis ME,Akil H,Watson SJ.Anatomy of CNS opioid receptors[J].Trends Neurosci,1988.11:308-314.
[47].Przewlocki R,Przewlocka B.Opioids in chronic pain.Eur J Pharmacol.2001,429:79-91.
[48].Richard J.Miller,Pedro Cuatrecasas.The enkaphalins:peptides with morphine-like activity[J].Naturwissenschaften.1978,65:507-514.
[49].Marotti T,Balog T,Munic V,Sobocanec S,Abramic M.The link between met-enkephalin-induced down-regulation of APN activity and the release of superoxide anion[J].Neuropeptides.2000;34:121-128.
[50].Noble.F.,Smadja C.,Pai-supressive effects on various nociceptive stimuli of the first orally active enkephalin-metabolizing enzyme inhibitor RB 101[J].Pain,73,383-391.
[51].Maldonado,R.Association of the peptidase inhibitor RB101 and a CCK-B antagonistic strongly enhances antinociceptive responses[J].NeuroReport,1993,4,947-950.
[52].Pulido-Cejudo G.,Conway B.,Proulx P.,et al.Bestatin-mediated inhibition of leucine aminopeptidase may hinder HIV infection[J].Antiviral Res.,1997,36(3):167-177.
[53].Christopherson K.2nd,Hromas R.Chemokine regulation of normal and pathologic immune responses[J].Stem Cells,2001,19(5):388-396.
[54].Deng H.,Liu R.,EUmeier W.,et al.Identification of a major co-receptor for primary isolates of HIV-1[J].Nature,1996,381(6584):661-666.
[55].Cocchi F.,Devico A.L.,Garzino-Demo A.,et al.Identification of RANTES,MIP-1α,and MIP-1β as the major HIV-suppressive factors produced by CDS+ T cells[J].Science,1995,270(5243):1811-1815.
[56].Kasman L.M.CD13/aminopeptidase N and murine cytomegalovirus infection[J].Virology,2005,334(1):1-9.
[57].Lerche C.,Vogel L.K.,Shapiro L.H.,et al.Human aminopeptidase N is encoded by 20exons[J].Mature.Genome,1996,7(9):712-713.
[58].Watt V.M.,Willard H.F.The human aminopeptidase N gene:Isolation,chromosome localization,and DNA polymorphism analysis[J].Hum.Genet.,1990,85(6):651-654.
[59].Thompson J.D.,Gibson T.J.,Plewniak F.,et al.The ClustalX windows interface:flexible strategies for multiple sequence alignment aided by quality analysis tools[J].Nucleic Acids Res.,1997,24:4876-4882.
[60].Rost N.D.,Barrett A.J.,MEROPS:the peptidase database[J].Nucl.Acida Res.2000,28(1):323-325.
[61]Sj(o|¨)str(o|¨)m H.,Noren O.,Olsen J.Structure and function of aminopeptidase N[B].Adv.Exp.Med.Biol.,2000,477:25-34.
[62].Onohara Y.,Nakajima Y.,Ito K.,et al.Crystallization and preliminary X-ray characterization of aminopeptidase N from Escherichia coli[J].Acta.Cryst.,2006,62(7):699-701.
[63]Ito K.,Nakajima Y.,Onohara Y.,et al.Crystal structure of aminopeptidase N (proteobacteria alanyl aminopeptidase) from Escherichia coli and conformational change of methionine 260 involved in substrate recognition[J].J.Biol.Chem.,2006,281(44):33664-33676.
[64]Addlagatta A.,Gay L.,Matthews B.W.Structure of aminopeptidase N from Escherichia coli suggests a compartmentalized,gated active site[J].Proc.Natl.Acad.Sci.U.S.A.,2006,103(36):13339-13344.
[65]Nocek B.,Mulligan R.,Bargassa M.,et al.Crystal structure of aminopeptidase N from human pathogen Neisseria meningitides[J].Proteins,2007,70(1):273-279.
[66].Luciani N.,Marie-Claire C.,Ruffet E.,et al.Characterization of Glu350 as a critical residue involved in the N-terminal amine binding site of aminopeptidase N(EC3.4.11.2):Insights into its mechanism of action[J].Biochemistry,1998,37(2):686-692.
[67].Rudberg P.C.,Tholander F.,Thunnissen M.M.,et al.Leukotriene A4hydrolase/aminopeptidase.Glutamate 271 is a catalytic residue with specific roles in two distinct enzyme mechanisms[J].J.Biol.Chem.,2002,277(2):1398-1404.
[68]Jiang W.,Bond J.S.,Families of metalloendopeptidases and their relationships[J].FEBS Lett.,1992,312(2-3):110-114.
[69].Hangauer D.G,Monzingo A.F.,Matthews B.W.An interactive computer graphics study of thermolysin-catalyzed peptide cleavage and inhibition by N-carboxymethyl dipeptides[J].Biochemistry.1984,23(24):5730-5741.
[70].Holmes M.A.,Matthews B.W.Binding of hydroxamic acid inhibitors to crystalline thermolysin suggests a pentacoordinate zinc intermediate in catalysis[J].Biochemistry.1981,20(24):6912-6920.
[71].Hanahan D.,Folkman J.Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis[J].Cell,1996,86(3):353-364.
[72].Curnis F.,Sacchi A.,Borgna L.,et al.Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N(CD13).Nat.Biotechnol.,2000,18(11):1185-1190.
[73].Ichinose Y.,Genka K.,Koike T.,et al.Randomized double-blind placebo-controlled trial of bestatin in patients with resected stage I squamous-cell lung carcinoma[J].J.Natl.Cancer Inst.,2003,95(8):605-610.
[74].Curnis F.,Gasparri A.,Sacchi A.,et al.Targeted Delivery of IFN{gamma} to Tumor Vessels Uncouples Antiturnor from Counterregulatory Mechanisms[J].Cancer Res.,2005,65(7):2906-2913.
[75]. Umezawa H., Aoyagi T., Suda H., et al. Bestatin, an inhibitor of aminopeptidase B, produced by actinomycetes[J]. J. Antibiot., 1976,29(1): 97-99.
[76]. Mathe G.Bestatin, an aminopeptidase inhibitor with a multi-pharmacological function[J]. Biomed. Pharmacother., 1991,45(2-3): 49-54.
[77]. Van Hensbergen Y., Broxterman H.J., Peters E., et al. Aminopeptidase inhibitor bestatin stimulates microvascular endothelial cell invasion in a fibrin matrix[J]. Thromb. Haemost., 2003,90(5): 921-929.
[78]. Ino K., Bierman P.J., Varney M.L., et al. Monocyte activation by an oral immunomodulator (bestatin) in lymphoma patients following autologous bone marrow transplantation[J]. Cancer Immunol. Immunother., 1996,43(4): 206-212.
[79]. Ota K., Kurita S. Immunotherapy with bestatin for acute non-Lymphocytic Leukemia(ANLL)in adults[J]. Jpn. J. Cancer Chemother., 1984,11(2): 2442-2750.
[80]. Ota K.,Kurita S. Results of investigation into prognosis immunotherapy with bestatin for acute nonlymphocytic Leukemia in adults[J]. Jpn.J.Cancer Chemother., 1986, 13(1):1017-1025
[81]. Ota K., Ogawa N. Randomized controlled study of chemoimmunotherapy with bestatin of acute nonlymphocytic leukemia in adults[J]. Biomed. Pharmacother., 1990,44(2): 93-101.
[82]. Aoyagi T., Tobe H., Kojima F., et al. Amastatin, an inhibitor of aminopeptidase A, produced by actinomycetes[J]. J. Antibiot., 1978, 31(6): 636-638.
[83]. Repic Lampret B., Kidric J., Kralj B., et al. Lapstatin, a new aminopeptidase inhibitor produced by Streptomyces rimosus, inhibits autogenous aminopeptidases[J]. Arch. Microbiol., 1999,171(6): 397-404.
[84]. Aoyagi T., Yoshida S., Nakamura Y., et al. Probestin, a new inhibitor of aminopeptidase M, produced by Streptomyces azureus MH663-2F6. I. Taxonomy, production, isolation, physico-chemical properties and biological activities[J]. J. Antibiot., 1990,43(2): 143-148.
[85]. Nagai M., Kojima F., Naganawa H., et al. Phebestin, a new inhibitor of aminopeptidase N, produced by Streptomyces sp. MJ716-m3[J]. J. Antibiot., 1997, 50(1): 82-84.
[86]. Shim J.S., Kim J.H., Cho H.Y., et al. Irreversible inhibition of APN/aminopeptidase N by the antiangiogenic agent curcumin[J]. Chem.Biol., 2003,10(8): 695-704.
[87]. Egan M.E., Pearson M., Weiner S.A., et al. Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects[J]. Science, 2004, 304(5670): 600-602.
[88]. Chung M.C., Lee H.J., Chun H.K., et al. Bestatin analogue from Streptomyces neyagawaensis SL-387 [J]. Biosci. Biotechnol. Biochem., 1996, 60(5): 898-900.
[89]. Shin J.S., Lee H.S., Shin J., et al. Psammaplin A, a marine natural product, inhibits aminopeptidase N and suppresses angiogenesis in vitro[J]. Cancer. Lett., 2004, 203(2): 163-169.
[90]. Melzig M.F., Bormann H. Betulinic acid inhibits aminopeptidase N activity [J]. Planta Med, 1998, 64(7): 655-657.
[91]. Aoyagi T., Yoshida S., Matsuda N., et al. Leuhistin, a new inhibitor of aminopeptidase M, produced by Bacillus laterosporus BMI156-14F1. I. Taxonomy, production, isolation, physico-chemical properties and biological activities[J]. J. Antibiot., 1991,44(6): 573-578.
[92] Sedo A., Vlasicova K., Bartak P., et al. Quaternary benzo[c]phenanthridine alkaloids as inhibitors of aminopeptidase N and dipeptidyl peptidase IV [J]. Phytoter. Res., 2002,16(1): 84-87.
[93]Huang K.,Takahara S.,Kinouchi T.,et al.Alanyl aminopeptidase from human seminal plasma:purification,characterization,and immunohistochemical localization in the male genital tract[J].J.Biochem.,1997,122(4):779-787.
[94]Yamamoto Y.,Li Y.H.,Ushiyama I.,et al.Puromyein-sensitive alanyl aminopeptidase from human liver cytosol:pudfieation and characterization[J].Forensic.Sci.Int.,2000,113(1-3):143.
[94].Giannousis P.P.,Bartlett P.A.Phosphorus amino acid analogues as inhibitors of leucine aminopeptidase[J].J.Med.Chem.,1987,30(9):1603-1609.
[95].Chen H.,Noble F.,Code P.,et al.Aminophosphinie inhibitors as transition state analogues of enkephalin-degrading enzymes:a class of central analgesics[J].Proc.Natl.Acad.Sci.U.S.A.,1998,95(20):12028-12033.
[96].Fournie-Zaluski M.,Code P.,Tureaud S.,et al.Potent and systemically active aminopeptidase N inhibitors designed from active-site investigation[J].J.Med.Chem.,1992,35(7):1259-1266.
[97].Bergin J.D.,Clapp C.H.Inhibition of aminopeptidase M by alkyl D- eysteinates[J].J.Enzym.Inhib.,1989,3(2):127-131.
[98].马涛,徐文方,王俊丽等.AHPA衍生物的设计、合成及抗癌活性研究[J].中国药物化学杂志,2003,13(2):70-75.
[99].Andersson L.,Isley T.C.,Wolfenden R.Alpha-aminoaldehydes:transition state analogue inhibitors of leucine aminopeptidase[J].Biochemistry,1982,21(17):4177-4180.
[100].Wang,J.,Xu,W.The preparation of novel L-iso-glutamine derivativesas potential antitumor agents.J.Chem.Res.Synop.,2003,12,789-791.
[101].Li,Q.B.,Xu,W.F.Novel 3-galloylamido-N'-substituted-2,6- piperidinedione-N-acetamide peptidomimeties as metalloproteinase inhibitors.Bioorganic & Medicinal Chemistry Letters,2007,17,2935-2938.
[102]Miyachi H.,Kato M.,Kato F.,et al.Novel potent nonpeptide aminopeptidase N inhibitors with a cyclic imide skeleton[J].J.Med.Chem.,1998,41(3):263-265.
[103].Takahashi H.,Komoda M.,Kakuta H.,et al.Preparation of novel specific aminopeptidase inhibitors with a cyclic imide skeleton[J].Yakugaku Zasshi,2000,120(10):909-921.
[104].Lee J.,Shim J.S.,Jung S.A.,et al.N-Hydroxy-2-(naphthalene -2-ylsulfanyl)-acetamide,a novel hydroxamie acid-based inhibitor of aminopeptidase N and its anti-angiogenic activity[J].Bioorg.Med.Chem.Lett.,2005,15(1):181-183.
[105].Lindsay C.K.,Gomez D.E.,Thorgeirsson U.P.Effect offlavone acetic acid on endothelial cell proliferation:evidence for antiangiogenic properties[J]..Anticancer Res.,1996,16(1):425-431.
[106].Bibby M.C.,Double J.A.Flavone acetic acid--from laboratory to clinic and back[J].AntiCancer Drugs,1993,4(1),3-17.
[107].Ocain T.D.,Rich D.H.Alpha-Keto amide inhibitors of aminopeptidases[J].J.Med.Chem.,1992,35(3):451-456.
[108].Ocain T.D.,Rich D.H.Synthesis of sulfur-containing analogues ofbestatin.Inhibition of aminopeptidases by alpha-thiolbestatin analogues[J].J.Med.Chem.,1988,31(11):2193-2199.
[109].Sehalk C.,d'Orchymont H.,Jauch M.F.,et al.3-Amino-2-tetralone derivatives:novel potent and selective inhibitors of aminopeptidase-M(EC 3.4.11.2)[J].Arch Biochem Biophys,1994,311(1):42-46.
[1].Onohara Y.,Nakajima Y.,Ito K.,et al.Crystallization and preliminary X-ray characterization of aminopeptidase N from Escherichia coli[J].Acta.Cryst.,2006,62(7):699-701.
[2].Sj(o|¨)str(o|¨)m H.,Noren O.,Olsen J.Structure and function of aminopeptidase N[B].Adv.Exp.Med.Biol.,2000,477:25-34.
[3].Luciani N.,Made-Claire C.,Ruffet E.,et al.Characterization of Glu350 as a critical residue involved in the N-terminal amine binding site of aminopeptidase N(EC3.4.11.2):Insights into its mechanism of action[J].Biochemistry,1998,37(2):686-692.
[4].Giannis A.,Rubsam F.Peptidomimetics in Drug Design[M].Adv.Drug.Res.,1997,29:1-78.
[5].Veselovsky AV,Ivanov AS.Strategy of computer-aided drug design[J].Curr Drug Targets Infect Disord,2003,3(1):33-40.
[6].Umezawa H.,Aoyagi T.,Suda H.,et al.Bestatin,an inhibitor of aminopeptidase B,produced by actinomycetes[J].J..Antibiot.,1976,29(1):97-99.
[7].Mathe G.Bestatin,an aminopeptidase inhibitor with a multi-pharmacological function[J].Biomed.Pharmacother.,1991,45(2-3):49-54.
[8].Chappelet-Tordo,D.,Lazdunski,C.,Murgier,M.,and Lazdunski,A.Aminopeptidase N from Escherichia coli:Ionizable active-center groups and substrate specificity.Eur.J.Biochem.1977,81,299-305.
[9].Anthony Addlagatta,Brian W.Matthews.Structural basis for the unusual specificity of Escherichia coli aminopeptidase N.Biochemistry,2008,47,5303-5311.
[10].Fournie-Zaluski M.,Corie P.,Tureaud S.,et al.Potent and systemically active aminopeptidase N inhibitors designed from active-site investigation[J].J.Med.Chem.,1992,35(7):1259-1266.
[11].Bergin J.D.,Clapp C.H.Inhibition of aminopeptidase M by aikyl D- cysteinates[J].J.Enzym.Inhib.,1989,3(2):127-131.
[1].Jordis.(1S,4S)-2-thia-5-azabicyclo[2.2.1]heptane.[J]Indian J Chem.Sec B.April 1989;294-296.
[2].Terry,R.;Daniel,T.W;Chu,sabella,et al.Design,synthesis,and properties of (4S)-7-(4-amino-2-substituted-pyrrolidin-1-yl)quinolone-3-carboxylic acids[J]J.Med.Chem.1988,31,1598-1611
[3].Alessandro Dondoni,[J]Organic Syntheses,Coll.2004,10,320.
[4].Sinha SK,Brew K.Synthesis of 4-deoxy-D-xylo-hexose and 4-azido-4-deoxy- D-glucose and their effects on lactose synthase[J].Carbohydr Res.1980,81(2):239-247.
[5].Warawa E J,Mueller NJ.Quinuclidine chemistry.4.Diuretic properties of cis-3-amino-2-benzhydrylquinuclidine[J].J Med Chem.1975,18(6):587-593.
[6].Samarendra N.Maiti.Alkaline earth metal mediated reduction of azides to amines.Synthetic Communications,1988,18(11),1201-1206.
[7].Chellemi F.Synthesis by conventional methods of human growth hormone peptide fragments[J].Int J Pept Protein Res,1975,7(2):43-48.
[8].Frank S.Gibson,Stephen C.Bergmeier.Selective Removal of an N-BOC Protecting Group in the Presence of a tert-Butyl Ester and Other Acid-Sensitive Groups[J].J.Org.Chem.1994,59(11):3216-3218.
[9].David Bartholomew,Michael J.Stocks.Intramolecular cyclisation-N- dealkylation of azetidine-3-acetic acids.Tetrahedron Lett.1991,32(36),4799-4800.
[10].Chen BC,Skoumbourdis AP,Guo P,et al A facile method for the transformation of N-(tert-butoxycarbonyl) α-amino acids to N-unprotected α-amino acids methyl esters [J].J Org Chem,1999,64(25):9294-9296.
[11].Alexandar McKillop,Richard J.K.Taylor,et al An improved procedure for the preparation of the garner aldehyde and its use for the synthesis of N-proteced 1-Halo-2-(R)-amino-3-butenes[J].Syntheis,1994,31-33.
[12].Lis R,Morgan TK,DeVita RJ,et al Synthesis and antiarrhythmic activity of novel 3-alkyl-1-[omega-[4-[(alkylsulfonyl) amino]phenyl]-omega- hydroxyalkyl]-1H-imidazolium salts and related compounds[J].JMed Chem.1987,30(4):696-704.
[13].Nishiyama K,Anselme JP.Deoxygenation of N-nitrosodibenzylamine with aryl azides[J].J Org Chem.1977,42(15):2636-2637.
[14].S.N Maiti,P.Spevak,A.V.N.Reddy.Alkaline earth metal mediated reduction of azides to amines.Synth.Commun.,1988,18(11):1201-1206.
[1].Drag M.,Grembecka J.,Pawelczak M.,et al.α-Aminoalkylphosphonates as a tool in experimental optimisation of P1 side chain shape of potential inhibitors in S1 pocket of leucineand neutral aminopeptidases[J].Eur.J.Med.Chem.,2005,40(8):764-771.
[2].Raniera Beti,Arlette Cattaneo,Jean-Mare Gaberil,et al.A novel N°-acetyl alanine aminopeptidase N from allomyces arbuscala[J].Biochemistry,2002;84:309-319.
[3].Teruki Shimizu,Kenji Tani,Kayoko Hase,et al.Aminopeptidase inhibitors bestatin and actinoin inhibit cell proliferation of myeloma cells predominantly by intracellular interactivity[J].Cancer Letter.2002;182:113-119.
[4].Baragi VM,Shaw B J,Renkiewicz RR,et al.A versatile assay for gelatinase using succinylated gelatin[J].Anal Biochem,2000,286(1):267-273.
[5].Baragi V.M.,Shaw B.I.,Renkiewicz R.R.,et al:A versatile assay for gelatinases using succinylated gelatin[J].Matrix Biol,2000,19:267-273.
[6].何静松,林茂芳,麦文渊,等.乌苯美司对人白血病细胞生长抑制及其机制探讨[J].浙江大学学报(医学版),2002,31(4):259-264.
[7].Kazuko Aoki,Tetsuo Oka,The role of Bestatin-sensitive aminopeptidase,angiotensin converting enzyme and thiorphan-sensitive enkaphlinase in the potency of enkephalins in the guinea-pig.[J]Japan.J.Pharmacol.1984,36:59-65.
[8].Toupkazu Hiranuma,et al.Almost complete protection from[Met~5]-Enkephalin -Arg~6-Gly~7-Leu~8(Met-enk-RGL) hydrolysis in membrane preparations by the combination of Amastatin,Captopril and Phosphoramidon[J].J.Pharma.Exep.Thera.1997,281(2):769-774.
[1].FlexXTM is distributed by Tripos Inc.,1699 South Hanley Rd.,St.Louis,Missouri,USA (http://www.tripos.com)
[2].Rarey M.,Kramer B.,Lengauer T.et al.A Fast Flexible Docking Method using an Incremental Construction Algorithm[J].J.Mol.Biol.,1996,261:470-489.
[3].BiopolymerTM is distributed by Tripos Inc.,1699 South Hanley Rd.,St.Louis,Missouri,USA(http://www.tripos.com)
[4].Kellenberger E.,Rodrigo J.,Muller P.et al.Comparative evaluation of eight docking tools for docking and virtual screening accuracy[J].Proteins.,2004,57(2):225-242.
[5].Berman H.M.,Westbrook J.,Feng Z.,et al.The Protein Data Bank[J].Nucleic Acids Res.,2000,28(1):235-242.
[6].Vajragupta O,Boonchoong P,Wongkrajang Y.Comparative quantitative structure-activity study of radical scavengers[J].Bioorg Med Chem,2000,8(11):2617-2628.
[7].Cramer RD 3rd,Patterson DE,Bunce JD.Recent advances in comparative molecular field analysis(CoMFA)[J].Prog Clin Biol Res.1989,291(1):161-165.
[8].SYBYL 7.0,Tripos Inc.:1699 South Hanley Rd.,St.Louis,Missouri,63144.
[2].Hooper N.M.Families of zinc metalloproteases[J].FEBS Lett.,1994,354(1):1-6.
[3].Antczak C.,De Meester I.,Bauvois B.Ectopeptidases in pathophysiology[J].Bioessays.2001,23(3):251-260.
[4].Flavio C.,Angelo,C.Differentiation binding of drugs containing the NGR motif to CDI3isoforms in tumor vessels,epithelia,and myeloid cells[J].Cancer Research.2002,62,867-874.
[5].Bauvois B.,Dauzonne D.Aminopeptidase-N/CD13(EC 3.4.11.2) inhibitors:chemistry,biological evaluations,and therapeutic prospects[J].Med.Res.Rev.,2006,26(1):88-130.
[6].Firla B.,Arndt M.,Frank K.,et al.Extracellular cysteines define ectopeptidase(APN,CD13)expression and function[J].Free Radical Biology Medicine,2002,32(7):584-595.
[7].Vlahovic P.,Stefanovic V.Kidney ectopeptidases.Structure,functions and clinical significance[J].Pathol Biol(Paris),1998,46(10):779-786.
[8].Noble F.,Banisadr G.,Jardinaud F.,et al.First discrete autoradiographic distribution of aminopeptidase N in various structure of rat brain and spinal cord using the selective iodinated inhibitor[125I]RB 129[J].Neuroscience,2001,105(2):479-488.
[9].Waksman G.,Bouboutou R.,Devin J.,et al.In vitro and in vivo effects of kelatorphan on enkephalin metabolism in rodent brain[J].Eur.J..Pharmacol.1985,117(2):233-243.
[10].Montiel J.L.,Cornille F.,Roques B.P.,et al.Nocieeptin/orphanin FQ metabolism:role of aminopeptidase and endopeptidase 24.15[J].J..Neurochem.1997,68(1 ):354-361.
[11].Sato Y.Role of aminopeptidase in angiogenesis[J].Biol.Pharm.Bull.,2004,27(6):772-776.
[12].Saiki I.,Fujii H.,Yoneda J.,et al.Role of aminopeptidase N(CD13) in tumor-cell invasion and extracellular matrix degradation[J].Int.J.Cancer,1993,54(1),137-143.
[13].Menrad A.,Speieher D.,Wacker J.,et al.Biochemical and functional characterization of aminopeptidase N expressed by human melanoma cells[j].Cancer Res.,1993,53(6):1450-1455.
[14].Gros C.,Giros B.,Schwartz J.C.Identification of aminopeptidase M as an enkephalin-inactivating enzyme in rat cerebral membranes[J].Biochemistry,1985,24(9):2179-2185.
[15].BalogT.,Marotti T.,SverkoV.,et al.Enkephalin degradating enzymes,in pheochromocytoma patients[J].Oncol.Rep.,2003,10(1):253-258.
[16].Mitsui T.,Nomura S.,Itakura A.,et al.Role of aminopeptidases in the blood pressure regulation[J].Biol.Pharm.Bull.,2004,27(6):768-771.
[17].Hattori A.,Tsujimoto M.Processing of antigenic peptides by aminopeptidases[J].Biol.Pharm.Bull.,2004,27(6):777-780.
[18]Bedir A.,Ozener I.C.,Emerk K.Urinary leucine aminopeptidase is a more sensitive indicator of early renal damage in non-insulin-dependent diabetics than microalbuminuria[J].Nephron,1996,74(1):110-113.
[19].ShimizuT.,Tani K.,HaseK.,et al.CD13/aminopeptidase N-induced lymphocyte involvement in inflamed joints of patients with rheumatoid arthritis[J].Arthritis.Rheum.,2002,46(9),2330-2338.
[20].Sloane P.D.,Zimmerman S.,Suchindran C.,et al.The public health impact of Alzheimer's disease,2000-2050:potential implication of treatment advances[J].Annu.Rev.Public Health,2002,23:213-231.
[21].Bauvois B.,Dauzonne D.Aminopeptidase-N/CD13(EC 3.4.11.2) inhibitors:chemistry,biological evaluations,and therapeutic prospects[J].Med.Res.Rev.,2006,26(1):88-130.
[22].Look A.T.,Ashmun R.A.,Shapiro L.H.,et al.Human myeloid plasma membrane glyeoprotein CDl3(gp150) is identical to aminopeotidase N[J].J.Clin.Invest.,1989,83(4):1299-1307.
[23].Soderberg C.,Giugni T.D.,Zaia J.A.,et al.CD13(human aminopeptidase N) mediates human eytomegalovirus infection[J].J.Virol.1993,67(11):6576-6585.
[24].Paola Mina-Osorio.The moonlighting enzyme CD13:old and new functions to target.Trends Mol Med.2008,14(8):361-71.
[25]Mitsui T.,Nomura S.,Itakura A.,et al.Role of aminopeptidases in the blood pressure regulation[J].Biol.Pharm.Bull.,2004,27(6):765-771.
[26].Salki I.,Fujii H.,Yoneda J.,et al.Role of aminopeptidase N(CD13) in tumor-cell invasion and extracellular matrix degradation[J].Int.J.Cancer,1993,54(1),137-143.
[27]Fujii H.,Nakajima M.,Saiki I.,et al.Human melanoma invasion and metastasis enhancement by high expression of aminopeptidase N/CD13[J].Clin.Exp.Metastasis,1995,13(5):337-344.
[28].Dixon J.,Kaklamanis L.,Turley H.,et al.Expression of aminopeptidase-n(CD 13) in normal tissues and malignant neoplasms of epithelial and lymphoid origin[J].J.Clin.Pathol.,1994,47(1):43-47.
[29].Sato Y.Role of aminopeptidase in angiogenesis[J].Biol.Pharm.Bull.,2004,27(6):772-776.
[30].Ishii K.,Usui S.,Sugimura Y.,et al.Aminopeptidase N regulated by zinc in human prostate participates in tumor cell invasion[J].Int.J.Cancer,2001,92(1):49-54.
[31].Kido A.,Krueger S.,Haeekel C.,et al.Inhibitory effect of antisense aminopeptidase N (APN/CD13) cDNA transfection on the invasive potential of osteosarcoma cells[J].Clin.Exp.Metastasis,2003,20(7):585-592.
[32].Hanahan D.,Folkman J.Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis[J].Cell,1996,86(3):353-364.
[33]Bhagwat S.V.,Petrovie N.,Okamoto Y.,et al.The angiogenie regulator CD13/APN is a transcriptional target of Ras signaling pathways in endothelial morphogenesis[J].Blood,2003,101(5):1818-1826.
[34].Ikeda N.,Nakajima Y.,Tokuhara T.et al.Clinical Significance of Aminopeptidase N/CD13Expression in Human Pancreatic Carcinoma[J].Clin.Cancer Res,,2003,9(4):1503-1508.
[35].Aozuka Y.,Koizumi K.,Saitoh Y.,et al:Anti-tumor angiogenesis effect of aminopeptidase inhibitor bestatin against B 16-BL6 melanoma cells orthotopically implanted into syngeneie mice[J].Cancer Lett.,2004,216(1):35-42.
[36].Bauvois B.Transmembrane proteases in cell growth and invasion:new contributors to angiogenesis[J].Oncogene,2004,23(2):317-329.
[37].Zetter B.R.Angiogenesis and tumor metastasis[J].Annu.Rev.Med,1995,49:407-424.
[38].Bussolino F.,Mantovani A.,Persico G.Molecular mechanisms of blood vessel formation[J].Trends Biochem.Sci.,1997,22(7):251-256.
[39].Scornik O.A.,Botbol V..Bestatin as experimental tool in mammals[J].Curr.Drug Metab., 2001,2(1):67-85.
[40].Alexander N.S.,Juergen Langner,Manfred Hem,ann,et al.Aminopeptadase N/CD13 is directly linked to signal transduction pathways in monocytes[J].Cell.Immunol.,2000,201(1):22-32
[41].Tani K.,Ogushi E,Huang L.,et al.CD13/aminopeptidase N,a Novel Chemoattractant for T Lymphocytes in Pulmonary Sarcoidosis[J].Am.J.Respir Crit.Care Med.,2000,161(5):1636-1642.
[42].Lohn M.,Mueller C.,Langner J.Cell cycle retardation in monocytoid cells induced by aminopeptidase N(CD13)[J].Leuk.Lymphoma.,2002,43(2):407-413.
[43].Cohen M.L.,Geary L.E.,Wiley K.S.Enkephalin degradation in the guinea-pig ileum:effect of aminopeptidase inhibitors,puromycin,and bestatin[J].J.Pharmacol.Exp.Ther.1983,224(2):379-385.
[44].Abroad S.,Wang L.,Ward P.E.Dipeptidyl(amino) peptidase Ⅳ and aminopeptidase M metabolize circulating substance P in vivo[J].J.Pharmacol.Exp.Ther,1992,260(3):1257-1261.
[45].Furuhashi M.,Mizutani S.,Kurauchi,O.,et al.In vitro degradation of opioid peptides by human placental aminopeptidase M[J].Exp.Clin.Endocrinol.,1988,92(2):235-237.
[46]Mansour A,Khachaturian H,Lewis ME,Akil H,Watson SJ.Anatomy of CNS opioid receptors[J].Trends Neurosci,1988.11:308-314.
[47].Przewlocki R,Przewlocka B.Opioids in chronic pain.Eur J Pharmacol.2001,429:79-91.
[48].Richard J.Miller,Pedro Cuatrecasas.The enkaphalins:peptides with morphine-like activity[J].Naturwissenschaften.1978,65:507-514.
[49].Marotti T,Balog T,Munic V,Sobocanec S,Abramic M.The link between met-enkephalin-induced down-regulation of APN activity and the release of superoxide anion[J].Neuropeptides.2000;34:121-128.
[50].Noble.F.,Smadja C.,Pai-supressive effects on various nociceptive stimuli of the first orally active enkephalin-metabolizing enzyme inhibitor RB 101[J].Pain,73,383-391.
[51].Maldonado,R.Association of the peptidase inhibitor RB101 and a CCK-B antagonistic strongly enhances antinociceptive responses[J].NeuroReport,1993,4,947-950.
[52].Pulido-Cejudo G.,Conway B.,Proulx P.,et al.Bestatin-mediated inhibition of leucine aminopeptidase may hinder HIV infection[J].Antiviral Res.,1997,36(3):167-177.
[53].Christopherson K.2nd,Hromas R.Chemokine regulation of normal and pathologic immune responses[J].Stem Cells,2001,19(5):388-396.
[54].Deng H.,Liu R.,EUmeier W.,et al.Identification of a major co-receptor for primary isolates of HIV-1[J].Nature,1996,381(6584):661-666.
[55].Cocchi F.,Devico A.L.,Garzino-Demo A.,et al.Identification of RANTES,MIP-1α,and MIP-1β as the major HIV-suppressive factors produced by CDS+ T cells[J].Science,1995,270(5243):1811-1815.
[56].Kasman L.M.CD13/aminopeptidase N and murine cytomegalovirus infection[J].Virology,2005,334(1):1-9.
[57].Lerche C.,Vogel L.K.,Shapiro L.H.,et al.Human aminopeptidase N is encoded by 20exons[J].Mature.Genome,1996,7(9):712-713.
[58].Watt V.M.,Willard H.F.The human aminopeptidase N gene:Isolation,chromosome localization,and DNA polymorphism analysis[J].Hum.Genet.,1990,85(6):651-654.
[59].Thompson J.D.,Gibson T.J.,Plewniak F.,et al.The ClustalX windows interface:flexible strategies for multiple sequence alignment aided by quality analysis tools[J].Nucleic Acids Res.,1997,24:4876-4882.
[60].Rost N.D.,Barrett A.J.,MEROPS:the peptidase database[J].Nucl.Acida Res.2000,28(1):323-325.
[61]Sj(o|¨)str(o|¨)m H.,Noren O.,Olsen J.Structure and function of aminopeptidase N[B].Adv.Exp.Med.Biol.,2000,477:25-34.
[62].Onohara Y.,Nakajima Y.,Ito K.,et al.Crystallization and preliminary X-ray characterization of aminopeptidase N from Escherichia coli[J].Acta.Cryst.,2006,62(7):699-701.
[63]Ito K.,Nakajima Y.,Onohara Y.,et al.Crystal structure of aminopeptidase N (proteobacteria alanyl aminopeptidase) from Escherichia coli and conformational change of methionine 260 involved in substrate recognition[J].J.Biol.Chem.,2006,281(44):33664-33676.
[64]Addlagatta A.,Gay L.,Matthews B.W.Structure of aminopeptidase N from Escherichia coli suggests a compartmentalized,gated active site[J].Proc.Natl.Acad.Sci.U.S.A.,2006,103(36):13339-13344.
[65]Nocek B.,Mulligan R.,Bargassa M.,et al.Crystal structure of aminopeptidase N from human pathogen Neisseria meningitides[J].Proteins,2007,70(1):273-279.
[66].Luciani N.,Marie-Claire C.,Ruffet E.,et al.Characterization of Glu350 as a critical residue involved in the N-terminal amine binding site of aminopeptidase N(EC3.4.11.2):Insights into its mechanism of action[J].Biochemistry,1998,37(2):686-692.
[67].Rudberg P.C.,Tholander F.,Thunnissen M.M.,et al.Leukotriene A4hydrolase/aminopeptidase.Glutamate 271 is a catalytic residue with specific roles in two distinct enzyme mechanisms[J].J.Biol.Chem.,2002,277(2):1398-1404.
[68]Jiang W.,Bond J.S.,Families of metalloendopeptidases and their relationships[J].FEBS Lett.,1992,312(2-3):110-114.
[69].Hangauer D.G,Monzingo A.F.,Matthews B.W.An interactive computer graphics study of thermolysin-catalyzed peptide cleavage and inhibition by N-carboxymethyl dipeptides[J].Biochemistry.1984,23(24):5730-5741.
[70].Holmes M.A.,Matthews B.W.Binding of hydroxamic acid inhibitors to crystalline thermolysin suggests a pentacoordinate zinc intermediate in catalysis[J].Biochemistry.1981,20(24):6912-6920.
[71].Hanahan D.,Folkman J.Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis[J].Cell,1996,86(3):353-364.
[72].Curnis F.,Sacchi A.,Borgna L.,et al.Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N(CD13).Nat.Biotechnol.,2000,18(11):1185-1190.
[73].Ichinose Y.,Genka K.,Koike T.,et al.Randomized double-blind placebo-controlled trial of bestatin in patients with resected stage I squamous-cell lung carcinoma[J].J.Natl.Cancer Inst.,2003,95(8):605-610.
[74].Curnis F.,Gasparri A.,Sacchi A.,et al.Targeted Delivery of IFN{gamma} to Tumor Vessels Uncouples Antiturnor from Counterregulatory Mechanisms[J].Cancer Res.,2005,65(7):2906-2913.
[75]. Umezawa H., Aoyagi T., Suda H., et al. Bestatin, an inhibitor of aminopeptidase B, produced by actinomycetes[J]. J. Antibiot., 1976,29(1): 97-99.
[76]. Mathe G.Bestatin, an aminopeptidase inhibitor with a multi-pharmacological function[J]. Biomed. Pharmacother., 1991,45(2-3): 49-54.
[77]. Van Hensbergen Y., Broxterman H.J., Peters E., et al. Aminopeptidase inhibitor bestatin stimulates microvascular endothelial cell invasion in a fibrin matrix[J]. Thromb. Haemost., 2003,90(5): 921-929.
[78]. Ino K., Bierman P.J., Varney M.L., et al. Monocyte activation by an oral immunomodulator (bestatin) in lymphoma patients following autologous bone marrow transplantation[J]. Cancer Immunol. Immunother., 1996,43(4): 206-212.
[79]. Ota K., Kurita S. Immunotherapy with bestatin for acute non-Lymphocytic Leukemia(ANLL)in adults[J]. Jpn. J. Cancer Chemother., 1984,11(2): 2442-2750.
[80]. Ota K.,Kurita S. Results of investigation into prognosis immunotherapy with bestatin for acute nonlymphocytic Leukemia in adults[J]. Jpn.J.Cancer Chemother., 1986, 13(1):1017-1025
[81]. Ota K., Ogawa N. Randomized controlled study of chemoimmunotherapy with bestatin of acute nonlymphocytic leukemia in adults[J]. Biomed. Pharmacother., 1990,44(2): 93-101.
[82]. Aoyagi T., Tobe H., Kojima F., et al. Amastatin, an inhibitor of aminopeptidase A, produced by actinomycetes[J]. J. Antibiot., 1978, 31(6): 636-638.
[83]. Repic Lampret B., Kidric J., Kralj B., et al. Lapstatin, a new aminopeptidase inhibitor produced by Streptomyces rimosus, inhibits autogenous aminopeptidases[J]. Arch. Microbiol., 1999,171(6): 397-404.
[84]. Aoyagi T., Yoshida S., Nakamura Y., et al. Probestin, a new inhibitor of aminopeptidase M, produced by Streptomyces azureus MH663-2F6. I. Taxonomy, production, isolation, physico-chemical properties and biological activities[J]. J. Antibiot., 1990,43(2): 143-148.
[85]. Nagai M., Kojima F., Naganawa H., et al. Phebestin, a new inhibitor of aminopeptidase N, produced by Streptomyces sp. MJ716-m3[J]. J. Antibiot., 1997, 50(1): 82-84.
[86]. Shim J.S., Kim J.H., Cho H.Y., et al. Irreversible inhibition of APN/aminopeptidase N by the antiangiogenic agent curcumin[J]. Chem.Biol., 2003,10(8): 695-704.
[87]. Egan M.E., Pearson M., Weiner S.A., et al. Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects[J]. Science, 2004, 304(5670): 600-602.
[88]. Chung M.C., Lee H.J., Chun H.K., et al. Bestatin analogue from Streptomyces neyagawaensis SL-387 [J]. Biosci. Biotechnol. Biochem., 1996, 60(5): 898-900.
[89]. Shin J.S., Lee H.S., Shin J., et al. Psammaplin A, a marine natural product, inhibits aminopeptidase N and suppresses angiogenesis in vitro[J]. Cancer. Lett., 2004, 203(2): 163-169.
[90]. Melzig M.F., Bormann H. Betulinic acid inhibits aminopeptidase N activity [J]. Planta Med, 1998, 64(7): 655-657.
[91]. Aoyagi T., Yoshida S., Matsuda N., et al. Leuhistin, a new inhibitor of aminopeptidase M, produced by Bacillus laterosporus BMI156-14F1. I. Taxonomy, production, isolation, physico-chemical properties and biological activities[J]. J. Antibiot., 1991,44(6): 573-578.
[92] Sedo A., Vlasicova K., Bartak P., et al. Quaternary benzo[c]phenanthridine alkaloids as inhibitors of aminopeptidase N and dipeptidyl peptidase IV [J]. Phytoter. Res., 2002,16(1): 84-87.
[93]Huang K.,Takahara S.,Kinouchi T.,et al.Alanyl aminopeptidase from human seminal plasma:purification,characterization,and immunohistochemical localization in the male genital tract[J].J.Biochem.,1997,122(4):779-787.
[94]Yamamoto Y.,Li Y.H.,Ushiyama I.,et al.Puromyein-sensitive alanyl aminopeptidase from human liver cytosol:pudfieation and characterization[J].Forensic.Sci.Int.,2000,113(1-3):143.
[94].Giannousis P.P.,Bartlett P.A.Phosphorus amino acid analogues as inhibitors of leucine aminopeptidase[J].J.Med.Chem.,1987,30(9):1603-1609.
[95].Chen H.,Noble F.,Code P.,et al.Aminophosphinie inhibitors as transition state analogues of enkephalin-degrading enzymes:a class of central analgesics[J].Proc.Natl.Acad.Sci.U.S.A.,1998,95(20):12028-12033.
[96].Fournie-Zaluski M.,Code P.,Tureaud S.,et al.Potent and systemically active aminopeptidase N inhibitors designed from active-site investigation[J].J.Med.Chem.,1992,35(7):1259-1266.
[97].Bergin J.D.,Clapp C.H.Inhibition of aminopeptidase M by alkyl D- eysteinates[J].J.Enzym.Inhib.,1989,3(2):127-131.
[98].马涛,徐文方,王俊丽等.AHPA衍生物的设计、合成及抗癌活性研究[J].中国药物化学杂志,2003,13(2):70-75.
[99].Andersson L.,Isley T.C.,Wolfenden R.Alpha-aminoaldehydes:transition state analogue inhibitors of leucine aminopeptidase[J].Biochemistry,1982,21(17):4177-4180.
[100].Wang,J.,Xu,W.The preparation of novel L-iso-glutamine derivativesas potential antitumor agents.J.Chem.Res.Synop.,2003,12,789-791.
[101].Li,Q.B.,Xu,W.F.Novel 3-galloylamido-N'-substituted-2,6- piperidinedione-N-acetamide peptidomimeties as metalloproteinase inhibitors.Bioorganic & Medicinal Chemistry Letters,2007,17,2935-2938.
[102]Miyachi H.,Kato M.,Kato F.,et al.Novel potent nonpeptide aminopeptidase N inhibitors with a cyclic imide skeleton[J].J.Med.Chem.,1998,41(3):263-265.
[103].Takahashi H.,Komoda M.,Kakuta H.,et al.Preparation of novel specific aminopeptidase inhibitors with a cyclic imide skeleton[J].Yakugaku Zasshi,2000,120(10):909-921.
[104].Lee J.,Shim J.S.,Jung S.A.,et al.N-Hydroxy-2-(naphthalene -2-ylsulfanyl)-acetamide,a novel hydroxamie acid-based inhibitor of aminopeptidase N and its anti-angiogenic activity[J].Bioorg.Med.Chem.Lett.,2005,15(1):181-183.
[105].Lindsay C.K.,Gomez D.E.,Thorgeirsson U.P.Effect offlavone acetic acid on endothelial cell proliferation:evidence for antiangiogenic properties[J]..Anticancer Res.,1996,16(1):425-431.
[106].Bibby M.C.,Double J.A.Flavone acetic acid--from laboratory to clinic and back[J].AntiCancer Drugs,1993,4(1),3-17.
[107].Ocain T.D.,Rich D.H.Alpha-Keto amide inhibitors of aminopeptidases[J].J.Med.Chem.,1992,35(3):451-456.
[108].Ocain T.D.,Rich D.H.Synthesis of sulfur-containing analogues ofbestatin.Inhibition of aminopeptidases by alpha-thiolbestatin analogues[J].J.Med.Chem.,1988,31(11):2193-2199.
[109].Sehalk C.,d'Orchymont H.,Jauch M.F.,et al.3-Amino-2-tetralone derivatives:novel potent and selective inhibitors of aminopeptidase-M(EC 3.4.11.2)[J].Arch Biochem Biophys,1994,311(1):42-46.
[1].Onohara Y.,Nakajima Y.,Ito K.,et al.Crystallization and preliminary X-ray characterization of aminopeptidase N from Escherichia coli[J].Acta.Cryst.,2006,62(7):699-701.
[2].Sj(o|¨)str(o|¨)m H.,Noren O.,Olsen J.Structure and function of aminopeptidase N[B].Adv.Exp.Med.Biol.,2000,477:25-34.
[3].Luciani N.,Made-Claire C.,Ruffet E.,et al.Characterization of Glu350 as a critical residue involved in the N-terminal amine binding site of aminopeptidase N(EC3.4.11.2):Insights into its mechanism of action[J].Biochemistry,1998,37(2):686-692.
[4].Giannis A.,Rubsam F.Peptidomimetics in Drug Design[M].Adv.Drug.Res.,1997,29:1-78.
[5].Veselovsky AV,Ivanov AS.Strategy of computer-aided drug design[J].Curr Drug Targets Infect Disord,2003,3(1):33-40.
[6].Umezawa H.,Aoyagi T.,Suda H.,et al.Bestatin,an inhibitor of aminopeptidase B,produced by actinomycetes[J].J..Antibiot.,1976,29(1):97-99.
[7].Mathe G.Bestatin,an aminopeptidase inhibitor with a multi-pharmacological function[J].Biomed.Pharmacother.,1991,45(2-3):49-54.
[8].Chappelet-Tordo,D.,Lazdunski,C.,Murgier,M.,and Lazdunski,A.Aminopeptidase N from Escherichia coli:Ionizable active-center groups and substrate specificity.Eur.J.Biochem.1977,81,299-305.
[9].Anthony Addlagatta,Brian W.Matthews.Structural basis for the unusual specificity of Escherichia coli aminopeptidase N.Biochemistry,2008,47,5303-5311.
[10].Fournie-Zaluski M.,Corie P.,Tureaud S.,et al.Potent and systemically active aminopeptidase N inhibitors designed from active-site investigation[J].J.Med.Chem.,1992,35(7):1259-1266.
[11].Bergin J.D.,Clapp C.H.Inhibition of aminopeptidase M by aikyl D- cysteinates[J].J.Enzym.Inhib.,1989,3(2):127-131.
[1].Jordis.(1S,4S)-2-thia-5-azabicyclo[2.2.1]heptane.[J]Indian J Chem.Sec B.April 1989;294-296.
[2].Terry,R.;Daniel,T.W;Chu,sabella,et al.Design,synthesis,and properties of (4S)-7-(4-amino-2-substituted-pyrrolidin-1-yl)quinolone-3-carboxylic acids[J]J.Med.Chem.1988,31,1598-1611
[3].Alessandro Dondoni,[J]Organic Syntheses,Coll.2004,10,320.
[4].Sinha SK,Brew K.Synthesis of 4-deoxy-D-xylo-hexose and 4-azido-4-deoxy- D-glucose and their effects on lactose synthase[J].Carbohydr Res.1980,81(2):239-247.
[5].Warawa E J,Mueller NJ.Quinuclidine chemistry.4.Diuretic properties of cis-3-amino-2-benzhydrylquinuclidine[J].J Med Chem.1975,18(6):587-593.
[6].Samarendra N.Maiti.Alkaline earth metal mediated reduction of azides to amines.Synthetic Communications,1988,18(11),1201-1206.
[7].Chellemi F.Synthesis by conventional methods of human growth hormone peptide fragments[J].Int J Pept Protein Res,1975,7(2):43-48.
[8].Frank S.Gibson,Stephen C.Bergmeier.Selective Removal of an N-BOC Protecting Group in the Presence of a tert-Butyl Ester and Other Acid-Sensitive Groups[J].J.Org.Chem.1994,59(11):3216-3218.
[9].David Bartholomew,Michael J.Stocks.Intramolecular cyclisation-N- dealkylation of azetidine-3-acetic acids.Tetrahedron Lett.1991,32(36),4799-4800.
[10].Chen BC,Skoumbourdis AP,Guo P,et al A facile method for the transformation of N-(tert-butoxycarbonyl) α-amino acids to N-unprotected α-amino acids methyl esters [J].J Org Chem,1999,64(25):9294-9296.
[11].Alexandar McKillop,Richard J.K.Taylor,et al An improved procedure for the preparation of the garner aldehyde and its use for the synthesis of N-proteced 1-Halo-2-(R)-amino-3-butenes[J].Syntheis,1994,31-33.
[12].Lis R,Morgan TK,DeVita RJ,et al Synthesis and antiarrhythmic activity of novel 3-alkyl-1-[omega-[4-[(alkylsulfonyl) amino]phenyl]-omega- hydroxyalkyl]-1H-imidazolium salts and related compounds[J].JMed Chem.1987,30(4):696-704.
[13].Nishiyama K,Anselme JP.Deoxygenation of N-nitrosodibenzylamine with aryl azides[J].J Org Chem.1977,42(15):2636-2637.
[14].S.N Maiti,P.Spevak,A.V.N.Reddy.Alkaline earth metal mediated reduction of azides to amines.Synth.Commun.,1988,18(11):1201-1206.
[1].Drag M.,Grembecka J.,Pawelczak M.,et al.α-Aminoalkylphosphonates as a tool in experimental optimisation of P1 side chain shape of potential inhibitors in S1 pocket of leucineand neutral aminopeptidases[J].Eur.J.Med.Chem.,2005,40(8):764-771.
[2].Raniera Beti,Arlette Cattaneo,Jean-Mare Gaberil,et al.A novel N°-acetyl alanine aminopeptidase N from allomyces arbuscala[J].Biochemistry,2002;84:309-319.
[3].Teruki Shimizu,Kenji Tani,Kayoko Hase,et al.Aminopeptidase inhibitors bestatin and actinoin inhibit cell proliferation of myeloma cells predominantly by intracellular interactivity[J].Cancer Letter.2002;182:113-119.
[4].Baragi VM,Shaw B J,Renkiewicz RR,et al.A versatile assay for gelatinase using succinylated gelatin[J].Anal Biochem,2000,286(1):267-273.
[5].Baragi V.M.,Shaw B.I.,Renkiewicz R.R.,et al:A versatile assay for gelatinases using succinylated gelatin[J].Matrix Biol,2000,19:267-273.
[6].何静松,林茂芳,麦文渊,等.乌苯美司对人白血病细胞生长抑制及其机制探讨[J].浙江大学学报(医学版),2002,31(4):259-264.
[7].Kazuko Aoki,Tetsuo Oka,The role of Bestatin-sensitive aminopeptidase,angiotensin converting enzyme and thiorphan-sensitive enkaphlinase in the potency of enkephalins in the guinea-pig.[J]Japan.J.Pharmacol.1984,36:59-65.
[8].Toupkazu Hiranuma,et al.Almost complete protection from[Met~5]-Enkephalin -Arg~6-Gly~7-Leu~8(Met-enk-RGL) hydrolysis in membrane preparations by the combination of Amastatin,Captopril and Phosphoramidon[J].J.Pharma.Exep.Thera.1997,281(2):769-774.
[1].FlexXTM is distributed by Tripos Inc.,1699 South Hanley Rd.,St.Louis,Missouri,USA (http://www.tripos.com)
[2].Rarey M.,Kramer B.,Lengauer T.et al.A Fast Flexible Docking Method using an Incremental Construction Algorithm[J].J.Mol.Biol.,1996,261:470-489.
[3].BiopolymerTM is distributed by Tripos Inc.,1699 South Hanley Rd.,St.Louis,Missouri,USA(http://www.tripos.com)
[4].Kellenberger E.,Rodrigo J.,Muller P.et al.Comparative evaluation of eight docking tools for docking and virtual screening accuracy[J].Proteins.,2004,57(2):225-242.
[5].Berman H.M.,Westbrook J.,Feng Z.,et al.The Protein Data Bank[J].Nucleic Acids Res.,2000,28(1):235-242.
[6].Vajragupta O,Boonchoong P,Wongkrajang Y.Comparative quantitative structure-activity study of radical scavengers[J].Bioorg Med Chem,2000,8(11):2617-2628.
[7].Cramer RD 3rd,Patterson DE,Bunce JD.Recent advances in comparative molecular field analysis(CoMFA)[J].Prog Clin Biol Res.1989,291(1):161-165.
[8].SYBYL 7.0,Tripos Inc.:1699 South Hanley Rd.,St.Louis,Missouri,63144.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |